Exercise serves as a potential non-pharmacological therapeutic modality to prevent, manage, and improve anthracycline-induced cardiotoxicities in cancer survivors.
Does exercise therapy prevent or manage anthracycline-induced cardiotoxicity in populations diagnosed with cancer?
Exercise cardio-oncology represents a promising non-pharmacological approach to mitigate anthracycline-induced cardiotoxicity, though more longitudinal clinical trials are needed.
Anthracyclines are one of the most effective chemotherapy agents and have revolutionized cancer therapy. However, anthracyclines can induce cardiac injuries through ‘multiple-hits', a series of cardiovascular insults coupled with lifestyle risk factors, which increase the risk of developing short- and long-term cardiac dysfunction and cardiovascular disease that potentially lead to premature mortality following cancer remission. Therefore, the management of anthracycline-induced cardiotoxicity is a serious unmet clinical need. Exercise therapy, as a non-pharmacological intervention, stimulates numerous biochemical and physiologic adaptations, including cardioprotective effects, through the cardiovascular system and cardiac muscles, where exercise has been proposed to be an effective clinical approach that can protect or reverse the cardiotoxicity from anthracyclines. Many preclinical and clinical trials demonstrate the potential impacts of exercise on cardiotoxicity; however, the underlying mechanisms as well as how to implement exercise in clinical settings to improve or protect against long-term cardiovascular disease outcomes are not clearly defined. In this review, we summarize the current evidence in the field of “exercise cardio-oncology” and emphasize the utilization of exercise to prevent and manage anthracycline-induced cardiotoxicities across high-risk and vulnerable populations diagnosed with cancer.
Kang et al. (Fri,) conducted a review in Anthracycline-Induced Cardiotoxicity. Exercise was evaluated. Exercise serves as a potential non-pharmacological therapeutic modality to prevent, manage, and improve anthracycline-induced cardiotoxicities in cancer survivors.